Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

大流行 焦虑 心理健康 2019年冠状病毒病(COVID-19) 医学 重性抑郁障碍 精神科 人口 全球卫生 疾病负担 萧条(经济学) 公共卫生 环境卫生 疾病 传染病(医学专业) 宏观经济学 病理 护理部 经济 认知
作者
Damian Santomauro,Ana Maria Mantilla Herrera,Jamileh Shadid,Peng Zheng,Charlie Ashbaugh,David M. Pigott,Cristiana Abbafati,Christopher Adolph,Joanne O Amlag,Aleksandr Y. Aravkin,Bree Bang-Jensen,Gregory J Bertolacci,Sabina Bloom,Rachel Castellano,Emma Castro,Suman Chakrabarti,Jhilik Chattopadhyay,Rebecca M Cogen,James K. Collins,Xiaochen Dai
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10312): 1700-1712 被引量:5043
标识
DOI:10.1016/s0140-6736(21)02143-7
摘要

Summary

Background

Before 2020, mental disorders were leading causes of the global health-related burden, with depressive and anxiety disorders being leading contributors to this burden. The emergence of the COVID-19 pandemic has created an environment where many determinants of poor mental health are exacerbated. The need for up-to-date information on the mental health impacts of COVID-19 in a way that informs health system responses is imperative. In this study, we aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020.

Methods

We conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021. We searched PubMed, Google Scholar, preprint servers, grey literature sources, and consulted experts. Eligible studies reported prevalence of depressive or anxiety disorders that were representative of the general population during the COVID-19 pandemic and had a pre-pandemic baseline. We used the assembled data in a meta-regression to estimate change in the prevalence of major depressive disorder and anxiety disorders between pre-pandemic and mid-pandemic (using periods as defined by each study) via COVID-19 impact indicators (human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate). We then used this model to estimate the change from pre-pandemic prevalence (estimated using Disease Modelling Meta-Regression version 2.1 [known as DisMod-MR 2.1]) by age, sex, and location. We used final prevalence estimates and disability weights to estimate years lived with disability and disability-adjusted life-years (DALYs) for major depressive disorder and anxiety disorders.

Findings

We identified 5683 unique data sources, of which 48 met inclusion criteria (46 studies met criteria for major depressive disorder and 27 for anxiety disorders). Two COVID-19 impact indicators, specifically daily SARS-CoV-2 infection rates and reductions in human mobility, were associated with increased prevalence of major depressive disorder (regression coefficient [B] 0·9 [95% uncertainty interval 0·1 to 1·8; p=0·029] for human mobility, 18·1 [7·9 to 28·3; p=0·0005] for daily SARS-CoV-2 infection) and anxiety disorders (0·9 [0·1 to 1·7; p=0·022] and 13·8 [10·7 to 17·0; p<0·0001]. Females were affected more by the pandemic than males (B 0·1 [0·1 to 0·2; p=0·0001] for major depressive disorder, 0·1 [0·1 to 0·2; p=0·0001] for anxiety disorders) and younger age groups were more affected than older age groups (−0·007 [–0·009 to −0·006; p=0·0001] for major depressive disorder, −0·003 [–0·005 to −0·002; p=0·0001] for anxiety disorders). We estimated that the locations hit hardest by the pandemic in 2020, as measured with decreased human mobility and daily SARS-CoV-2 infection rate, had the greatest increases in prevalence of major depressive disorder and anxiety disorders. We estimated an additional 53·2 million (44·8 to 62·9) cases of major depressive disorder globally (an increase of 27·6% [25·1 to 30·3]) due to the COVID-19 pandemic, such that the total prevalence was 3152·9 cases (2722·5 to 3654·5) per 100 000 population. We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6) per 100 000 population. Altogether, major depressive disorder caused 49·4 million (33·6 to 68·7) DALYs and anxiety disorders caused 44·5 million (30·2 to 62·5) DALYs globally in 2020.

Interpretation

This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option.

Funding

Queensland Health, National Health and Medical Research Council, and the Bill and Melinda Gates Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美少女不战斗士完成签到,获得积分10
1秒前
那朵云完成签到 ,获得积分10
2秒前
maodou完成签到,获得积分10
2秒前
提醒我完成签到,获得积分10
3秒前
哆啦A梦完成签到 ,获得积分10
3秒前
4秒前
7秒前
Niann发布了新的文献求助10
7秒前
柔弱的立果完成签到 ,获得积分10
9秒前
安安完成签到 ,获得积分10
9秒前
御剑风形完成签到 ,获得积分10
9秒前
帅古斯塔完成签到,获得积分10
9秒前
超级的冷菱完成签到 ,获得积分10
9秒前
英俊的冰棍完成签到 ,获得积分10
10秒前
科研通AI2S的应助被M83采纳,获得10
12秒前
直率若烟完成签到 ,获得积分10
12秒前
pyp发布了新的文献求助10
14秒前
djfnf完成签到,获得积分10
14秒前
爆米花的应助被飘逸的沛柔采纳,获得10
16秒前
liuzhiliang完成签到 ,获得积分10
16秒前
18秒前
yanmh完成签到,获得积分10
18秒前
lulufighting完成签到,获得积分10
18秒前
我爱自由民权完成签到,获得积分10
18秒前
19秒前
犹豫机器猫完成签到,获得积分10
20秒前
顺利刺猬完成签到 ,获得积分10
22秒前
aa121599发布了新的文献求助10
23秒前
24秒前
M83发布了新的文献求助10
24秒前
科研老兵完成签到,获得积分10
27秒前
小二郎的应助被陈烨采纳,获得10
29秒前
meta完成签到,获得积分10
32秒前
shaw完成签到,获得积分10
32秒前
hebnkygzs完成签到 ,获得积分10
32秒前
懵懂的莺完成签到,获得积分10
33秒前
ljj完成签到,获得积分10
34秒前
35秒前
碧蓝丹烟完成签到,获得积分10
35秒前
jklling完成签到 ,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370